We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
At Profacgen, our Caco-2 Permeability Assay Services deliver gold-standard prediction of human intestinal absorption, bidirectional transport characterization, and efflux liability assessment for protein degraders, small molecules, and oral drug candidates.
Caco-2 cells, a human colon epithelial carcinoma cell line, express transporter proteins, efflux proteins, and Phase II conjugation enzymes to mimic various transcellular pathways as well as metabolic transformation of test substances. When cultured as a monolayer, Caco-2 cells differentiate to form tight junctions between cells, serving as a model for passive diffusion and active transport across the intestinal epithelium. Under specific culture conditions, Caco-2 cells become polarized with intercellular tight junctions, a well-differentiated brush border, and typical small intestinal nutrient transporters, very similar to enterocytes lining the small intestine. Due to these advantages, Caco-2 permeability has become the gold standard method for evaluating passive and active transport and absorption of orally administered drugs.
Figure 1. Conventional transwell plate and schematic diagram of Caco-2 cell model (Ding et al., 2020).
Overview
The Caco-2 model is the most widely accepted cell-based system for predicting human intestinal absorption and characterizing drug transport mechanisms:
Human intestinal epithelial cell model: Caco-2 cells differentiate into polarized enterocyte-like monolayers with apical brush borders, tight junctions, and basolateral membrane domains. This morphology closely resembles human small intestine epithelium, enabling physiologically relevant absorption prediction
Passive and active transport: The model captures both passive diffusion (transcellular and paracellular) and active transport processes including nutrient transporters, efflux pumps (P-glycoprotein, BCRP, MRP2), and Phase II conjugation enzymes. The major functional limitation is lack of cytochrome P450 expression, particularly CYP3A4
Oral absorption prediction: Caco-2 apparent permeability (Papp) correlates with human fractional absorption, enabling biopharmaceutical classification and formulation strategy decisions. The regulatory agencies accept Caco-2 data for BCS biowaivers and IND submissions
Drug permeability assessment: Beyond absorption prediction, Caco-2 identifies permeability liabilities, efflux-mediated drug-drug interactions, and transport mechanism contributions that guide medicinal chemistry optimization
Our Assay Capabilities
Profacgen provides comprehensive Caco-2 transport studies tailored to diverse compound types and program requirements:
Bidirectional Transport Studies
Apical-to-basolateral (A-B) and basolateral-to-apical (B-A) permeability assessment.
A-B transport: Prediction of intestinal absorption from luminal to serosal direction
B-A transport: Detection of efflux-mediated secretion and active transport
Mass balance: Recovery assessment to identify metabolism, adsorption, or stability issues
Apparent Permeability (Papp) Determination
Quantitative permeability classification with validated binning criteria.
Low permeability: Papp ≤ 0.500 × 10−6 cm/s
Moderate permeability: 0.500 < Papp < 2.50 × 10−6 cm/s
High permeability: Papp ≥ 2.50 × 10−6 cm/s
LC-MS/MS quantification for sensitive, specific compound detection
Efflux Ratio Evaluation
Identification of active efflux and transporter-mediated drug interactions.
Efflux ratio calculation: B-A Papp / A-B Papp; values > 2 indicate active efflux
P-gp inhibition: Verapamil or cyclosporin A co-treatment to confirm P-glycoprotein contribution
Transporter specificity: Customized inhibition studies for BCRP, MRP2, and other efflux pumps
Transport Mechanism Analysis
Dissection of passive versus active transport contributions.
Temperature dependence: 4°C versus 37°C comparison to identify active transport
pH dependence: Assessment of ionization state effects on permeability
Concentration dependence: Saturation kinetics for carrier-mediated transport
Applications
Our Caco-2 permeability assay supports diverse drug discovery and development applications:
Protein degraders: Assessment of PROTAC cellular uptake and oral absorption potential. Caco-2 identifies permeability liabilities in large, polar degraders and guides linker/warhead modification to improve intestinal absorption while maintaining degradation potency
Small molecule drug candidates: Biopharmaceutical classification, formulation strategy, and route-of-administration decisions. Caco-2 data supports BCS biowaivers and regulatory submissions for immediate-release oral products
Lead optimization: Structure-permeability relationship development correlating chemical modifications with Papp changes. Identification of efflux liabilities and optimization strategies to improve absorption and reduce drug-drug interaction potential
Oral drug development: Prediction of human intestinal absorption, food effect assessment, and formulation-dependent permeability changes. Integration with solubility and metabolism data to forecast oral bioavailability
Gold Standard Human Intestinal Model: Differentiated Caco-2 monolayers with validated tight junctions, brush borders, and transporter expression provide the most physiologically relevant absorption prediction available.
High-Throughput Capability: 24-well and 96-well Transwell formats enable parallel screening of compound libraries with minimal compound consumption, supporting rapid lead optimization cycles.
Efflux and Transporter Characterization: Bidirectional studies with specific inhibitors identify P-gp, BCRP, and MRP2 contributions, guiding structure modification to overcome efflux liabilities and reduce drug-drug interaction risk.
Extensive PROTAC Expertise: Profacgen has accumulated substantial experience in protein degrader permeability assessment, understanding the unique challenges of large molecular weight, polar surface area, and linker optimization.
Representative Program Scenarios
Scenario 1: PROTAC Lead Optimization by Caco-2 Permeability Screening
Program Context:
A PROTAC series demonstrated potent cellular degradation but poor oral bioavailability. The team required rapid, quantitative permeability screening to identify structure-permeability relationships and guide medicinal chemistry.
Objective:
To rank 25 PROTAC analogs by Caco-2 Papp, identify efflux liabilities, and correlate permeability with physicochemical properties and cellular potency.
Approach:
Profacgen established Caco-2 monolayers in 96-well Transwell format with TEER validation (>400 Ω·cm²). Analogs were screened at 10 µM in A-B and B-A directions with LC-MS/MS quantification. Efflux ratios were calculated and P-gp contribution assessed by verapamil co-treatment. Data were correlated with molecular weight, polar surface area, and calculated lipophilicity.
Outcome:
Caco-2 screening identified a clear permeability cliff at polar surface area >150 Ų. Three analogs below this threshold achieved moderate permeability (Papp 0.8–1.2 × 10−6 cm/s) with acceptable efflux ratios (<3). These analogs demonstrated 5-fold improved oral bioavailability in mouse PK studies, validating Caco-2 as a predictive filter for PROTAC optimization.
Scenario 2: Efflux Liability Identification for BCS Classification
Program Context:
A small molecule kinase inhibitor required BCS classification for biowaiver eligibility. The compound showed good passive permeability but required confirmation of minimal efflux liability.
Objective:
To perform bidirectional Caco-2 transport with efflux inhibition to classify permeability and support regulatory submission.
Approach:
Profacgen conducted A-B and B-A transport studies at three concentrations with and without the P-gp inhibitor cyclosporin A. Monolayer integrity was verified by Lucifer yellow permeability (<1% per hour). Mass balance was assessed to exclude stability issues. The efflux ratio was calculated and compared to reference compounds (atenolol, propranolol).
Outcome:
The compound achieved high A-B permeability (Papp = 4.2 × 10−6 cm/s) with an efflux ratio of 1.3, indicating minimal active efflux. Cyclosporin A did not alter transport, confirming P-gp independence. The data supported BCS Class I classification and successful biowaiver application, accelerating development timelines.
Q: Why is Caco-2 considered the gold standard for intestinal absorption?
A: Caco-2 cells differentiate into polarized enterocyte-like monolayers with tight junctions, brush borders, and functional transporters closely resembling human small intestine. Papp values correlate with human fractional absorption, and the model is accepted by regulatory agencies for BCS biowaivers and regulatory submissions.
Q: What is the difference between Caco-2 and MDCK?
A: Caco-2 is a human colon epithelial line with enterocyte-like differentiation, expressing multiple transporters and efflux pumps. MDCK is a canine kidney line with tighter monolayers and faster growth, suitable for high-throughput screening but lacking human intestinal transporter expression. Caco-2 is preferred for absorption prediction; MDCK for rapid transport screening.
Q: Can Caco-2 predict oral bioavailability?
A: Caco-2 Papp correlates with intestinal absorption fraction but not complete oral bioavailability, which also depends on solubility, metabolism, and first-pass extraction. We integrate Caco-2 permeability with solubility and metabolic stability data to predict overall bioavailability more accurately.
Q: How do you validate monolayer integrity?
A: We verify integrity by transepithelial electrical resistance (TEER > 400 Ω·cm²) and Lucifer yellow permeability (< 1% per hour). These measurements confirm tight junction formation and exclude paracellular leakage that would confound permeability results.
Q: What compound concentration and volume do you require?
A: We typically require 1–2 mg compound at >98% purity for a full bidirectional study with multiple concentrations. DMSO stock solutions (10 mM) are preferred. Final assay concentrations range from 1–50 µM depending on solubility and analytical sensitivity. We provide detailed submission guidelines upon project initiation.
Q: What is the typical turnaround for Caco-2 studies?
A: Monolayer differentiation requires 21 days. Single compound bidirectional transport with LC-MS/MS analysis delivers within 3–4 weeks from compound receipt. High-throughput screening of 20–50 compounds in 96-well format requires 4–6 weeks. Rush services are available for urgent timelines.
References:
Ding X, Hu X, Chen Y, et al. Differentiated Caco-2 cell models in food-intestine interaction study: Current applications and future trends. Trends in Food Science & Technology. 2021;107:455-465. doi:10.1016/j.tifs.2020.11.015
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Conventional transwell plate and schematic diagram of Caco-2 cell model (Ding et al., 2020).